Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | ACACB | O00763 | 9/20 | 0.37 |
| ▸ | ACACA | Q13085 | 6/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | CKS1B | P61024 | 1/20 | 0.36 |
| ▸ | SKP1 | P63208 | 1/20 | 0.36 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL145227 | 1.00 | DRD2 (0.39) | DRD2KMT2AACACBACACANAMPT | |
| SCHEMBL141254 | 0.86 | DRD2 (0.41) | DRD2KMT2AACACBACACANAMPT | |
| SCHEMBL142693 | 0.86 | DRD2 (0.41) | DRD2KMT2AACACBACACANAMPT | |
| SCHEMBL142444 | 0.83 | DRD2 (0.39) | DRD2KMT2AACACBACACANAMPT | |
| SCHEMBL144373 | 0.83 | DRD2 (0.39) | DRD2KMT2AACACBACACANAMPT | |
| SCHEMBL143514 | 0.81 | CTSK (0.41) | KMT2ACTSK | |
| SCHEMBL147425 | 0.81 | CTSK (0.41) | KMT2ACTSK | |
| SCHEMBL142161 | 0.81 | CTSK (0.41) | KMT2ACTSK | |
| SCHEMBL139448 | 0.81 | CTSK (0.41) | KMT2ACTSK | |
| SCHEMBL141440 | 0.77 | DRD2 (0.40) | DRD2KMT2AACACBACACANAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120058989-A1 | ANTIBACTERIAL FLUOROQUINOLONE ANALOGS | ACHAOGEN, INC. (US) | 2012-03-08 | — | — | US | disclosed |
| EP-2250171-A2 | ANTIBACTERIAL FLUOROQUINOLONE ANALOGS | Achaogen, Inc. (US) | 2010-11-17 | — | — | EP | disclosed |
| WO-2009137130-A2 | ANTIBACTERIAL FLUOROQUINOLONE ANALOGS | ACHAOGEN, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058989-A1 | ANTIBACTERIAL FLUOROQUINOLONE ANALOGS | RECQL, BLVRB, NQO2 | DRD2 198/4885KMT2A 4780/4885ACACB 3854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.